New obesity drug shows promise in early trial
NCT ID NCT06313528
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested a new drug called LY3437943 in 85 people with obesity. Participants received either the drug or a placebo, and researchers measured how many calories they ate and how their bodies used energy. The goal was to see if the drug could help control appetite and metabolism under a reduced-calorie diet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3437943
What this could lead to
If successful, this could point toward a new treatment option for obesity that helps control appetite and energy use.
What could go wrong
This is an early Phase 1 study with only 85 participants, so results may not apply broadly. The drug may not show meaningful benefits or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Orlando
Orlando, Florida, 32804, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States